{"id":2163,"date":"2007-09-03T13:29:38","date_gmt":"2007-09-03T12:29:38","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2163"},"modified":"2013-09-12T17:08:31","modified_gmt":"2013-09-12T17:08:31","slug":"first-paediatric-fixed-dose-triple-combination-pedimune-is-approved-by-fda-for-use-in-pepfar","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2163","title":{"rendered":"First paediatric fixed dose triple combination (Pedimune) is approved by FDA for use in PEPFAR"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>On 13 August 2007, the FDA granted tentative approval for purchase under PEPFAR of Pedimune baby, the paediatric triple fixed-dose combination (FDC) of 3TC, d4T and nevirapine.<\/strong><\/p>\n<p>This is the first fixed-dose antiretroviral product designed to treat children under the age of 12 years.<\/p>\n<p>As with adult FDCs containing nevirapine, paediatric patients can use it twice daily once they have 14 days of lead-in treatment with nevirapine, taken once daily. The tablet can also be dissolved in water for children who cannot swallow pills.<\/p>\n<p>As a result of this approval the FDC will be also included on the list maintained by the WHO prequalification programme.<\/p>\n<p>Source: FDA website<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base On 13 August 2007, the FDA granted tentative approval for purchase under PEPFAR of Pedimune baby, the paediatric triple fixed-dose combination (FDC) of 3TC, d4T and nevirapine. This is the first fixed-dose antiretroviral product designed to &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32],"tags":[],"class_list":["post-2163","post","type-post","status-publish","format-standard","hentry","category-paediatric-care"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2163"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2163\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}